Cannabidiol is a negative allosteric modulator of the cannabinoid CB 1 receptor

Laprairie, R B, Bagher, A M, Kelly, M E M, Denovan‐Wright, E M·2015·British Journal of Pharmacology
DOI 10.1111/bph.13250

Cited by (1,000)

Items 701–800 of 1,000

  1. Pharmacodynamics of cannabinoids
    Alexandra Šulcová · 2019 · Archives of Pharmacy and Pharmaceutical Sciences
  2. Cannabinoids and Brain Damage: A Systematic Review on a Frequently Overlooked Issue
    Matteo Scopetti, Donato Morena, Federico Manetti, Alessandro Santurro, Nicola Di Fazio, Stefano D’Errico, Martina Padovano, Paola Frati, Vittorio Fineschi · 2022 · Current Pharmaceutical Biotechnology
  3. CBD’s potential impact on Parkinson’s disease: An updated overview
    Hafida El Ghachi, Rachid Soulimani, Halima Gamrani, Najib Kissani · 2024 · Open Medicine
  4. Cannabidiol attenuates precuneus activation during appetitive cue exposure in individuals with alcohol use disorder
    Tristan P. Hurzeler, Warren Logge, Joshua Watt, Iain S. McGregor, Anastasia S. Suraev, Paul Haber, Kirsten C. Morley · 2025 · European Archives of Psychiatry and Clinical Neuroscience
  5. Overview of the Endocannabinoid System and Endocannabinoidome
    Mellar P. Davis · 2022 · Springer eBooks
  6. A 1:1 ratio of cannabidiol: tetrahydrocannabinol attenuates methamphetamine conditioned place preference in mice: A prospective study of antidopaminergic mechanism
    Jakkrit Nukitram, Ekkasit Kumarnsit, Dania Cheaha · 2022 · Brain Research Bulletin
  7. Oral Cannabis consumption and intraperitoneal THC:CBD dosing results in changes in brain and plasma neurochemicals and endocannabinoids in mice
    Nichole A. Reisdorph, Katrina Doenges, Cassandra L. Levens, Jonathan Manke, Michael Armstrong, Harry Smith, Kevin D. Quinn, Richard A. Radcliffe, Richard M. Reisdorph, Laura M. Saba et al. · 2024 · Journal of Cannabis Research
  8. Therapeutic potential of cannabidiol in depression
    Matti Bock Guldager, Adriano Maia Chaves Filho, Caroline Biojone, Sâmia R.L. Joca · 2024 · International review of neurobiology
  9. Chronic cannabidiol treatment induces cardiovascular improvement in renovascular hypertensive rats
    Atalia Ferreira de Lima Flôr, Samuel Duarte-Maia, Francineide Fernandes-Costa, Rayane Maria Pessoa de Souza, Valdir A. Braga, Sandra L. Amaral, Sandra Rodrigues‐Mascarenhas, José Luiz de Brito Alves, Débora Simoes Almeida Colombari, Josiane C. Cruz · 2024 · Journal of Hypertension
  10. Cannabinoids for treating psychiatric disorders in youth: a systematic review of randomized controlled trials
    Patrick Köck, Andrzej Badek, Maximilian Meyer, Arndt-Lukas Klaassen, Marc Walter, Jochen Kindler · 2024 · Child and Adolescent Psychiatry and Mental Health
  11. Renal Outcomes and Other Adverse Effects of Cannabinoid Supplementation
    Ewelina Młynarska, Natalia Kustosik, Maja Mejza, Zuzanna Łysoń, Dawid Delebis, Jakub Orliński, Jacek Rysz, Beata Franczyk · 2024 · Nutrients
  12. Profiling Allosteric Modulators of CB 1 R with an Allosteric Fluoroprobe
    Miroslav Kosar, Themiya Perera, Rudolf L. Z. Ganzoni, Roman C. Sarott, Leire Borrega‐Roman, Rosa Maria Vitale, Alessia Ligresti, Arne Christian Rufer, Wolfgang Guba, Uwe Grether et al. · 2025 · Angewandte Chemie International Edition
  13. Plant-Based Modulators of Endocannabinoid Signaling
    Christopher W. Cunningham · 2019 · Journal of Natural Products
  14. Cannabidiol use among patients with substance use disorders
    Patrik Roser, Benedikt Habermeyer, Norbert Scherbaum, Barbara Lay · 2022 · Journal of Substance Use
  15. The effects of cannabidiol on behavioural and oxidative stress parameters induced by prolonged haloperidol administration
    Jaiyeola Abiola Kajero, Soraya Seedat, JUDE UZOMA OHAERI, Abidemi James Akindele, Oluwagbemiga Olanrewaju Aina · 2022 · Acta Neuropsychiatrica
  16. Cyclic Vomiting Syndrome and Cannabis Hyperemesis Syndrome
    James R. Lathrop, Sheldon N. Rosen, Margaret McLean Heitkemper, Diana Taibi Buchanan · 2023 · Gastroenterology Nursing
  17. Cannabis Sativa Oil Promotes Social Interaction and Ultrasonic Communication by Acting on Oxytocin Pathway
    Marika Premoli, Marinella Carone, Andrea Mastinu, Giuseppina Maccarinelli, Francesca Aria, Eileen Mac Sweeney, Maurizio Memo, Sara Anna Bonini · 2024 · Cannabis and Cannabinoid Research
  18. Explaining Contemporary Patterns of Cannabis Teratology
    A. Reece, G. Hulse · 2019 · UWA Profiles and Research Repository (University of Western Australia)
  19. Therapeutic Effects of Cannabidiol on Methamphetamine Abuse: A Review of Preclinical Study.
    Yasaman Razavi, Fariborz Keyhanfar, Ronak Shabani, Abbas Haghparast, Mehdi Mehdizadeh · 2021 · PubMed Central
  20. Can cannabidiol have an analgesic effect?
    Bartłomiej Kulesza, Marek Mazurek, Jacek Kurzepa · 2023 · Fundamental and Clinical Pharmacology
  21. Cannabinoids-based Medicine Pharmacology, Drug Interactions, and Perioperative Management of Surgical Patients
    Samer Narouze, Natalie H. Strand, Priodarshi Roychoudhury · 2020 · Advances in Anesthesia
  22. Cannabidiol improves L-DOPA-induced dyskinesia and modulates neuroinflammation and the endocannabinoid, endovanilloid and nitrergic systems
    Glauce Crivelaro Nascimento, Gabriela Gonçalves Bálico, Bianca Andretto de Mattos, Maurício dos Santos Pereira, Igor Gustavo Carvalho Oliveira, Maria Eugênia Costa Queiroz, Lilian Carmo Heck, Luiz Carlos Carvalho Navegantes, Francisco Silveira Guimarães, Elaine Del-Bel · 2025 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
  23. Endocannabinoids, depression, and treatment resistance: Perspectives on effective therapeutic interventions
    Ilenia Rosa, Lorenzo Pio Padula, Francesco Semeraro, Carlotta Marrangone, Antonio Inserra, Luisa De Risio, Marta Boffa, Francesca Zoratto, Marta Borgi, Roberto Guidotti et al. · 2025 · Psychiatry Research
  24. Combination treatment with medium dose THC and CBD had no therapeutic effect in a transgenic mouse model for Alzheimer's disease but affected other domains including anxiety-related behaviours and object recognition memory
    Beate Aumer, Rossana Rosa Porto, Madilyn Coles, Nina Ulmer, Georgia Watt, Heike Kielstein, Tim Karl · 2025 · Pharmacology Biochemistry and Behavior
  25. Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?
    Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D’Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura · 2025 · British Journal of Pharmacology
  26. Cannabidiol as a candidate pharmacotherapy for sleep disturbance in alcohol use disorder
    Marie N. S. Gendy, Benicio Noronha Frey, Michael Van Ameringen, Nirushi Kuhathasan, James M. MacKillop · 2023 · Alcohol and Alcoholism
  27. Cannabinoid Hyperemesis Syndrome (CHS) - An emerging gastrointestinal disorder and clinical challenge
    Robin B. McFee · 2024 · Disease-a-Month
  28. The Role of Cannabis within an Emerging Perspective on Schizophrenia
    Jegason P. Diviant, Jacob Miguel Vigil, Sarah See Stith · 2018 · Medicines
  29. Putative effects of cannabidiol in depression and synaptic plasticity
    Sâmia R.L. Joca, Gabriela Pandini Silote, Ariandra Guerini Sartim, Amanda J. Sales, Francisco Silveira Guimarães, Gregers Wegener · 2021 · Elsevier eBooks
  30. Serum Proteomic Analysis of Cannabis Use Disorder in Male Patients
    Fawaz F. Alasmari, Sary Alsanea, Assim Abdulaziz Alfadda, Ibrahim O. Alanazi, Mohthash Musambil, Afshan Masood, Faleh Alqahtani, Omer I. Fantoukh, Abdullah F. Alasmari, Hicham Benabdelkamel · 2021 · Molecules
  31. Investigation of Cannabidiol in the Mouse Drug Discrimination Paradigm
    Mohammed Ahmed Mustafa, Justin L. Poklis, Kimberly N. Karin, Jayden A. Elmer, Joseph H. Porter, Victoria Parra, Dai Lu, Joel E. Schlosburg, Aron H. Lichtman · 2023 · Cannabis and Cannabinoid Research
  32. A Cannabinoid Receptor 1 Agonist Reduces Light-induced Phase Delays in Male But Not Female Mice
    Timothy D. Niepokny, Eric M. Mintz · 2023 · Journal of Biological Rhythms
  33. Effects of Cannabidiol on the Functions of Chimeric Antigen Receptor T Cells in Hematologic Malignancies
    Natthida Chantarat, Kristine Cate S. Pe, Koramit Suppipat, Sornkanok Vimolmangkang, Supannikar Tawinwung · 2023 · Cannabis and Cannabinoid Research
  34. CBD Versus CBDP: Comparing In Vitro Receptor-Binding Activities
    Mehdi Haghdoost, Scott Young, Alisha K. Holloway, Matthew Roberts, Ivori A. Zvorsky, Marcel O. Bonn‐Miller · 2024 · International Journal of Molecular Sciences
  35. Analgesic Properties of Next-Generation Modulators of Endocannabinoid Signaling: Leveraging Modern Tools for the Development of Novel Therapeutics
    Simar J. Singh, Kaylin J. Ellioff, Michael R. Bruchas, Benjamin Bruce Land, Nephi Stella · 2024 · Journal of Pharmacology and Experimental Therapeutics
  36. UK medical cannabis registry: an updated clinical outcomes analysis of patients with post-traumatic stress disorder
    Aritra Datta, Simon Erridge, John Julian Warner-Levy, Eleanor Clarke, Katy McLachlan, Ross Coomber, Muhammad Sohaib Asghar, Urmila Bhoskar, Matthieu Crews, Andrea De Angelis et al. · 2025 · Expert Review of Neurotherapeutics
  37. Cannabidiol in the management of bruxism in behavioral variant of frontotemporal degeneration
    Stefanie Danielle Piña‐Escudero, Maira Okada de Oliveira, Alisson Snyder, Bruce L. Miller · 2021 · Neurocase
  38. Cannabidiol Treatment Shows Therapeutic Efficacy in a Rodent Model of Social Transfer of Pain in Pair-Housed Male Mice
    Lígia Renata Rodrigues Tavares, Leonardo Abdelnur Petrilli, Daniela Baptista‐de‐Souza, Lucas Canto‐de‐Souza, Cleopatra S. Planeta, Francisco Silveira Guimarães, Ricardo Luiz Nunes‐de‐Souza, Azair Canto‐de‐Souza · 2023 · Cannabis and Cannabinoid Research
  39. Regulation of Cannabinoid and Opioid Receptor Levels by Endogenous and Pharmacological Chaperones
    Achla Gupta, Ivone Gomes, Aya Osman, Wakako Fujita, Lakshmi A. Devi · 2024 · Journal of Pharmacology and Experimental Therapeutics
  40. Modulation of Pain by Endocannabinoids in the Periphery
    Megan L. Uhelski, Iryna A. Khasabova, Donald A. Simone · 2019 · IntechOpen eBooks
  41. CSF Levels of the Endocannabinoid Anandamide are Reduced in Patients with Untreated Narcolepsy Type 1: A Pilot Study
    Andrea Romigi, Monica Bari, Claudio Liguori, Francesca Izzi, Cinzia Rapino, Marzia Nuccetelli, Natalia Battista, Sergio Bernardini, Diego Centonze, Nicola Biagio Mercuri et al. · 2020 · CNS & Neurological Disorders - Drug Targets
  42. Regulation and marketing of cannabidiol-containing products in European countries. Pharmacists’ knowledge in Bulgaria
    Bogdan Kirilov, Margarita Zhelyazkova, Elina S. Petkova-Gueorguieva, Georgi Momekov · 2020 · Biotechnology & Biotechnological Equipment
  43. Cannabinoids and Pain: Mechanisms of Action
    Samer Narouze · 2021 · Springer eBooks
  44. Alternative and Complimentary Medication Use in Singers: A Pilot Survey
    Granit Mavraj, Bailey Balouch, Ghiath Alnouri, Robert Thayer Sataloff · 2022 · Journal of Voice
  45. What is currently known about cannabidiol and ocular pressure
    Alex J. Straiker · 2019 · Expert Review of Ophthalmology
  46. The effects of cannabidiol on cue- and stress-induced reinstatement of cocaine seeking behavior in mice are reverted by the CB1 receptor antagonist AM4113
    Miguel Ángel Luján, Laia Alegre-Zurano, Ana Martín‐Sánchez, Olga Valverde · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  47. A journey through cannabidiol in Parkinson’s disease
    Elaine Del-Bel, Núbia Barros, Rafaela Aparecida Ponciano da Silva de Moraes, Bianca Andretto de Mattos, Thaís Antônia Alves-Fernandes, Lorena Borges de Abreu, Glauce Crivelaro Nascimento, Daniela Maria Escobar-Espinal, João Francisco Cordeiro Pedrazzi, Gabrielle A. Jacob et al. · 2024 · International review of neurobiology
  48. Cannabielsoin (CBE), a CBD Oxidation Product, Is a Biased CB1 Agonist
    Mehdi Haghdoost, Scott Young, Matthew Roberts, Caitlyn Krebs, Marcel O. Bonn‐Miller · 2024 · Biomedicines
  49. Development of Squaramides as Allosteric Modulators of the CB1 Receptor: Synthesis, Computational Studies, Biological Characterization, and Effects against Cocaine-Induced Behavioral Sensitization and Reinstatement in Rats
    Thuy Nguyen, Ann M. Decker, Daniel G. Barrus, Chi Hyuck Song, Jianfeng Liu, Thomas F. Gamage, Danni L. Harris, Jun‐Xu Li, Yanan Zhang · 2025 · Journal of Medicinal Chemistry
  50. Recent Preclinical Evidence on Phytocannabinoids in Neurodegenerative Disorders: A Focus on Parkinson’s and Alzheimer’s Disease
    Nicoleta Mirela Blebea, Ciprian Pușcașu, Gabriel Hancu, Alina Mihaela Stăniguț, Cornel Chiriță · 2025 · Pharmaceuticals
  51. Cannabidiol improves metabolic profiles and alleviates liver inflammation and fibrosis in conditions of androgenic obesity and polycystic ovary syndrome
    Francisco J. Ponce‐Díaz, Francisco Ruíz-Pino, Martín Garrido‐Rodríguez, María E. Prados, Esperanza Uceda‐Rodriguez, Laura Cerero‐Tejero, Yolanda Guerrero‐Ruiz, Miguel Angel Sanchez-Garrido, Eduardo Muñóz, Manuel Tena‐Sempere · 2025 · Diabetes Obesity and Metabolism
  52. Therapeutic potential of cannabinoids for treating atopic dermatitis
    Adriel Aparecido Geraldo Stoco, Priscila Gava Mazzola · 2025 · Journal of Cannabis Research
  53. Acute cannabidiol (CBD), tetrahydrocannabinol (THC) and their mixture (THC:CBD) exert differential effects on brain activity and blood flow in rats: A translational neuroimaging study
    Eilidh MacNicol, Michelle Kokkinou, Maria Elisa Serrano Navacerrada, Donna-Michelle Smith, Jennifer S.Y. Li, Camilla Simmons, Eugene Kim, Michel Soares Mesquita, Loreto Rojo Gonzalez, Tanya Andrews et al. · 2025 · Journal of Psychopharmacology
  54. Therapeutic Profile of Cannabidiol in the Broad Symptomatology of Autism Spectrum Disorder: Evidence From Basic Science to Clinical Approaches
    João Francisco Cordeiro Pedrazzi, Lucas Hassib, Frederico Rogério Ferreira · 2023 · Psychiatric Annals
  55. Effects of CB1 receptor negative allosteric modulator Org27569 on oxycodone withdrawal symptoms in mice
    Rhianne L. Scicluna, Nicholas Adams Everett, Connie J. Badolato, Bianca B. Wilson, Michael T. Bowen · 2024 · Psychopharmacology
  56. Decoding the Therapeutic Potential of Cannabis and Cannabinoids in Neurological Disorders
    Mayur Bhimrao Kale, Mohit D. Umare, Nitu L. Wankhede, Rohitas Deshmukh, Vikrant Abbot, Md. Khalid Anwer, Brijesh Gulabrao Taksande, Aman Babanrao Upaganlawar, Milind Janrao Umekar, Seema Ramniwas et al. · 2024 · Current Pharmaceutical Design
  57. Cannabidiol Plays a Modulatory Function on the Methamphetamine-Induced Reward Through Hippocampal D2-Like Dopamine Receptors
    Mahsa Mohammadi, Seyed Erfan Omidiani, Ronak Azizbeigi, Abbas Haghparast · 2024 · Neurochemical Research
  58. Do Delta-9-tetrahydrocannabinol and Cannabidiol have opposed effects on male fertility?
    Olivia L M Scandlan, Laura A. Favetta · 2024 · Toxicology Letters
  59. Isobolographic interactions of cannabidiol and AM 1172 with cisplatin in human neuroblastoma and glioblastoma cell lines: An in vitro study
    Katarzyna Załuska-Ogryzek, Paula Wróblewska-Łuczka, Agnieszka Góralczyk, Jarogniew Jacek Łuszczki · 2025 · Chemico-Biological Interactions
  60. GC–MS as a valuable tool for analysing cannabinoid-containing gummies and identifying the synthetic process used for their production
    Arianna Bini, E. Roda, Stefano Protti, Luca Morini, Antonella Profumo, Marco Cavallo, Adolfo Gregori, C. Locatelli, Daniele Merli · 2025 · Forensic Chemistry
  61. Cannabidiol and cognition: a literature review of human randomized controlled trials
    Jyotpal Singh, Chase J. Ellingson, M. Abdullah Shafiq, Jane Alcorn, J. Patrick Neary · 2025 · Behavioural Pharmacology
  62. Endocannabinoid system in trauma and psychosis: distant guardian of mental stability
    Tomasz Bielawski, Lucas Albrechet‐Souza, Dorota Frydecka · 2021 · Reviews in the Neurosciences
  63. Methamphetamine Blocks Adenosine A2A Receptor Activation via Sigma 1 and Cannabinoid CB1 Receptors
    Mireia Casanovas, Irene Reyes‐Resina, Alejandro Lillo, Jaume Lillo, Raúl López‐Arnau, Jorge Camarasa, Elena Escubedo, Gemma Navarro, Rafael Franco · 2021 · International Journal of Molecular Sciences
  64. Efficacy of topical cannabinoids in the management of pain: a systematic review and meta-analysis of animal studies
    Lukas D. Linde, Carey M Ogryzlo, Cassandra M. Choles, Brian Edwin Cairns, John L. K. Kramer · 2022 · Regional Anesthesia & Pain Medicine
  65. Cannabis-Based Products in a Neurological Setting: A Clinical and Pharmacokinetic Survey
    Susan Mohamed, Giovanna Lopane, Loredana Sabattini, Cinzia Scandellari, Diletta Zardi, Vincenzo Angelo Donadio, Giovanni Rizzo, Alessandro Perrone, Alessandra Lugaresi, Manuela Contin · 2022 · Frontiers in Neurology
  66. Molecular Findings Guiding the Modulation of the Endocannabinoid System as a Potential Target to Treat Schizophrenia
    Giuliana S. Zuccoli, Caroline Brandão‐Teles, Gabriela Maciel Vieira, Felipe V. Gomes, Fernanda Crunfli · 2022 · Advances in experimental medicine and biology
  67. Impact of adolescent THC exposure on later adulthood: Focus on mesocorticolimbic function and behaviors
    Anthony English, Benjamin Bruce Land, Nephi Stella · 2022 · Elsevier eBooks
  68. Cannabidiolic Acid Rescues Deficits in Hippocampal Long-Term Potentiation in Models of Alzheimer’s Disease: An Electrophysiological and Proteomic Analysis
    Beatriz Gil, Mairéad Sullivan, Caitríona Scaife, Jeffrey Colm Glennon, Caroline E. Herron · 2025 · International Journal of Molecular Sciences
  69. CBD attenuates amygdala response to negative emotional stimuli in individuals with alcohol use disorder – a randomized controlled trial
    Marlen Pfisterer, Anton Teetzmann, Sina Vetter, Joscha Baeßler, Lena Schreckenberger, Judith Zaiser, Manuel Stenger, Patrick Bach · 2025 · Psychopharmacology
  70. Efficacy of a 20:1 CBD:THC cannabis herbal extract for pain and inflammation in dogs following tibial plateau leveling osteotomy
    Chloe Lyons, K. Romany Pinto, Kira Penney, Laura Holmes, Abdul Salama, Jane Alcorn, Alan L. Chicoine · 2025 · Frontiers in Veterinary Science
  71. Molecular targets of cannabinoids and their derivatives in epilepsy – a review with focus on CBD
    Sebastian Marciniak, Weronika Wasyluk, Andrzej Wojtak · 2025 · Acta Biochimica Polonica
  72. Cannabinoids rescue migraine symptoms caused by central CGRP administration in mice
    Erik Zorrilla, Thomas L. Duong, Cassandra L. Piña, Andrew F. Russo · 2025 · Cephalalgia
  73. Spent hemp biomass as a feed ingredient for beef steers: effects on performance, blood parameters, behavior, cannabinoid residues, and consumer exposure levels
    Agung Irawan, D. Hasan, Jenifer Cruickshank, Charles T. Estill, Serkan Ateş, Erminio Trevisi, Juliana Ranches, Brian P. Dolan, Massimo Bionaz · 2025 · animal
  74. Effects of prenatal cannabis exposure on offspring mental health: A focus on the role of the immune system
    Haley A. Vecchiarelli, Samantha L. Baglot, Tallan Black, Esther Y. Choi, Lani Cupo, Colby Sandberg, Léa Siron, M. Mallar Chakravarty, Matthew N. Hill, John G. Howland et al. · 2025 · Neuroscience & Biobehavioral Reviews
  75. Cannabidiol reduces oxycodone self-administration while preserving its analgesic efficacy in a rat model of neuropathic pain
    Adriaan W. Bruijnzeel, Azin Behnood‐Rod, Ranjithkumar Chellian, Wendi L. Malphurs, Robert M. Caudle, Marcelo Febo, Barry Setlow, Niall P. Murphy, John K. Neubert · 2026 · Scientific Reports
  76. Cannabidiol for the treatment of positive and negative symptoms in schizophrenia spectrum disorders: a systematic review and meta-analysis
    Antonio Di Francesco, Pierfelice Cutrufelli, Cecilia Chiarenza, Luca Zambuto, Carmen Concerto, Ludovico Mineo, Antonino Petralia, Marco Catalfo, Alessandro Rodolico, Myrto T. Samara et al. · 2026 · European Archives of Psychiatry and Clinical Neuroscience
  77. The role of cannabinoids in the management of symptoms in palliative care patients
    Michał Graczyk, Wojciech Leppert · 2021 · Palliative Medicine in Practice
  78. Cannabidiol reverses myeloperoxidase hyperactivity in the prefrontal cortex and striatum, and reduces protein carbonyls in the hippocampus in a ketamine-induced schizophrenia rat model
    Sofia de Almeida Queiroz, Linério Ribeiro de Novais Júnior, Anita Beatriz Pacheco de Carvalho, Tiago Vicente da Silva, Suelen de Souza Ramos, Vicente Meneguzzo, Khiany Mathias, Anita Dal Bó Tiscoski, Natália Piacentini, Mariana Pereira de Souza Goldim et al. · 2025 · Schizophrenia Research
  79. Investigation in the CB1 and CB2 receptor binding profile and intrinsic activity of (−) and (+)-enantiomers of some naturally occurring phytocannabinoids or synthetic derivatives
    Santiago Rodríguez-Carreiro, María Gómez‐Cañas, Francesca Lubrini, Claudia Gonzalo‐Consuegra, Matthias Winkler, Diego Caprioglio, Giovanni Appendino, Concepción García, Paula Morales, Nadine Jagerovic et al. · 2025 · European Journal of Medicinal Chemistry Reports
  80. Crosstalk Between Signaling Stroke Cascade and Therapeutic Receptors PPAR-γ, ROCK, CB1R, and CB2R: From Mechanism to Therapies
    Mrugendra Bhojraj Potdar, Rohit P Bhamare, Yogeeta O. Agrawal, Aarti V. Belgamwar · 2025 · Translational Stroke Research
  81. Effects of cannabidiol (CBD) treatment on age-related cognitive decline in C57 mice
    Behroo Mirza Agha, Merrin Monteith, Jarem Earl, Keona Ganske, Tina Kaloa, Kelan J. McDonald, Abigail G. Nixon, Maleeha Panjwani, Danika Robinson, Valeria Rusnak et al. · 2025 · Frontiers in Aging Neuroscience
  82. Adolescent cannabidiol treatment produces antidepressant-like effects without compromising long-term cognition in rats
    Laura Gálvez‐Melero, Itziar Beruete-Fresnillo, Sandra Ledesma‐Corvi, María Julia García-Fuster · 2025 · Pharmacological Reports
  83. Cats and cannabinoids: past, present and future
    Stephen Niño Cital, Joseph J. Wakshlag, Amanda Kennedy, David Tittle, Mike Petty · 2025 · Journal of Feline Medicine and Surgery
  84. The Endocannabinoid System in Local and Systemic Inflammation
    Melanie E. M. Kelly, Christine Lehmann, Juan Zhou · 2017 · Colloquium Series on Integrated Systems Physiology From Molecule to Function
  85. Cannabidiol as a Treatment for Seizures, Convulsions and Epilepsy
    Brian F. Thomas · 2017 · Springer eBooks
  86. Medical cannabis ad its significance for current medicine
    Leoš Landa, Jan Juřica, Václav Trojan, Regina Demlová, Radovan Hřib · 2023 · Anesteziologie a intenzivní medicína
  87. Clinical Pharmacology of Cannabinoid Therapeutics: Drug Interactions and Side Effects
    Ingolf Cascorbi · 2023 · Clinical Pharmacology & Therapeutics
  88. Assessment of Innovative Pharmacological Targets in Schizophrenia
    Teresa Reynolds de Sousa, Marta Ribeiro, Filipa Novais · 2024 · Current Treatment Options in Psychiatry
  89. Oral cannabidiol did not impair learning and memory in healthy adults
    Hanna H. Gebregzi, Joanna S. Zeiger, Jeffrey P. Smith, Libby Stuyt, Luann Cullen, Jim Carsella, Daniel C. Rogers, Jordan Lafebre, Jennah Knalfec, A. Perez-De Vargas et al. · 2025 · Journal of Cannabis Research
  90. Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review
    Paul J. Christo, Eugene Vortsman, Christopher G. Gharibo, Jo Ann LeQuang, Joseph V. Pergolizzi · 2025 · Cureus
  91. Novel Machaeriol Analogues as Modulators of Cannabinoid Receptors: Structure–Activity Relationships of (+)-Hexahydrocannabinoids and Their Isoform Selectivities
    Saqlain Haider, Pankaj Pandey, Chada Raji Reddy, Janet A. Lambert, Amar Gopal Chittiboyina · 2021 · ACS Omega
  92. Staff awareness of the use of cannabidiol (CBD): a trust-wide survey study in the UK
    Obioha Ukaegbu, Jared G. Smith, David John Hall, Thomas Frain, Cyrus Abbasian · 2021 · Journal of Cannabis Research
  93. Cannabis and Driving: Developing Guidelines for Safety Policies
    Federico Manetti, Silvio Chericoni, Anna M. Marrocco, Matteo Scopetti, Martina Padovano, Alessandro Santurro, Paola Frati, Mario Gabbrielli, Vittorio Fineschi · 2022 · Current Pharmaceutical Biotechnology
  94. Proposed mechanisms of cannabinoid hyperemesis syndrome—how can cannabinoid pathways both relieve and cause vomiting?
    Keith A. Sharkey · 2022 · Elsevier eBooks
  95. Pros and Cons of Cannabinoids as a Potential Therapeutic Target for Treating Parkinson's Disease
    Mahesh Pattabhiramaiah, Shanthala Mallikarjunaiah, Baishali Bedi Sarma · 2023 · Advances in medical diagnosis, treatment, and care (AMDTC) book series
  96. Drug interactions with Cannabis sativa: Mechanisms and clinical implication
    Atena Hasanpoor, Maryam Akaberi, Prashant Kesharwani, Zahra Sobhani, Amirhossein Sahebkar · 2023 · Annales de Toxicologie Analytique
  97. The Endogenous Cannabinoid System: A Cadre of Potential Therapeutic Targets
    Steven G. Kinsey, Aron H. Lichtman · 2018 · Springer eBooks
  98. Cannabinoids and Mental Health, Part 2: The Search for Clinical Applications
    Andrew Penn · 2019 · Journal of Psychosocial Nursing and Mental Health Services
  99. Daring discourse – yes: practical considerations for cannabis use in the perioperative setting
    Hance A. Clarke, Priodarshi Roychoudhury, Karim Shiraz Ladha, Timothy Sean Leroux, Joseph Fiorellino, Alexander Huang, Lakshmi P. Kotra · 2020 · Regional Anesthesia & Pain Medicine
  100. Cannabinoids and Pain
    Oliver Hulland, Jessica C. Oswald · 2021 · Rheumatic Disease Clinics of North America